Total neoadjuvant therapy versus standard neoadjuvant treatment strategies for the management of locally advanced rectal cancer: network meta-analysis of randomized clinical trials

Abstract Background This study compared the advantages and disadvantages of total neoadjuvant therapy (TNT) strategies for patients with locally advanced rectal cancer, compared with the more traditional multimodal neoadjuvant management strategies of long-course chemoradiotherapy (LCRT) or short-co...

Full description

Saved in:
Bibliographic Details
Published inBritish journal of surgery Vol. 110; no. 10; pp. 1316 - 1330
Main Authors Donnelly, Mark, Ryan, Odhrán K, Ryan, Éanna J, Creavin, Ben, O’Reilly, Mary, McDermott, Ray, Kennelly, Rory, Hanly, Ann, Martin, Seán T, Winter, Des C
Format Journal Article
LanguageEnglish
Published US Oxford University Press 06.09.2023
Online AccessGet full text

Cover

Loading…
Abstract Abstract Background This study compared the advantages and disadvantages of total neoadjuvant therapy (TNT) strategies for patients with locally advanced rectal cancer, compared with the more traditional multimodal neoadjuvant management strategies of long-course chemoradiotherapy (LCRT) or short-course radiotherapy (SCRT). Methods A systematic review and network meta-analysis of exclusively RCTs was undertaken, comparing survival, recurrence, pathological, radiological, and oncological outcomes. The last date of the search was 14 December 2022. Results In total, 15 RCTs involving 4602 patients with locally advanced rectal cancer, conducted between 2004 and 2022, were included. TNT improved overall survival compared with LCRT (HR 0.73, 95 per cent credible interval 0.60 to 0.92) and SCRT (HR 0.67, 0.47 to 0.95). TNT also improved rates of distant metastasis compared with LCRT (HR 0.81, 0.69 to 0.97). Reduced overall recurrence was observed for TNT compared with LCRT (HR 0.87, 0.76 to 0.99). TNT showed an improved pCR compared with both LCRT (risk ratio (RR) 1.60, 1.36 to 1.90) and SCRT (RR 11.32, 5.00 to 30.73). TNT also showed an improvement in cCR compared with LCRT (RR 1.68, 1.08 to 2.64). There was no difference between treatments in disease-free survival, local recurrence, R0 resection, treatment toxicity or treatment compliance. Conclusion This study provides further evidence that TNT has improved survival and recurrence benefits compared with current standards of care, and may increase the number of patients suitable for organ preservation, without negatively influencing treatment toxicity or compliance. This study has demonstrated that total neoadjuvant therapy (TNT) has improved survival and recurrence benefits compared with current standards of care. TNT treatment strategies also improve radiological and oncological responses to treatment, and may increase the number of patients suitable for organ preservation, without negatively influencing treatment toxicity or compliance.
AbstractList BACKGROUNDThis study compared the advantages and disadvantages of total neoadjuvant therapy (TNT) strategies for patients with locally advanced rectal cancer, compared with the more traditional multimodal neoadjuvant management strategies of long-course chemoradiotherapy (LCRT) or short-course radiotherapy (SCRT). METHODSA systematic review and network meta-analysis of exclusively RCTs was undertaken, comparing survival, recurrence, pathological, radiological, and oncological outcomes. The last date of the search was 14 December 2022. RESULTSIn total, 15 RCTs involving 4602 patients with locally advanced rectal cancer, conducted between 2004 and 2022, were included. TNT improved overall survival compared with LCRT (HR 0.73, 95 per cent credible interval 0.60 to 0.92) and SCRT (HR 0.67, 0.47 to 0.95). TNT also improved rates of distant metastasis compared with LCRT (HR 0.81, 0.69 to 0.97). Reduced overall recurrence was observed for TNT compared with LCRT (HR 0.87, 0.76 to 0.99). TNT showed an improved pCR compared with both LCRT (risk ratio (RR) 1.60, 1.36 to 1.90) and SCRT (RR 11.32, 5.00 to 30.73). TNT also showed an improvement in cCR compared with LCRT (RR 1.68, 1.08 to 2.64). There was no difference between treatments in disease-free survival, local recurrence, R0 resection, treatment toxicity or treatment compliance. CONCLUSIONThis study provides further evidence that TNT has improved survival and recurrence benefits compared with current standards of care, and may increase the number of patients suitable for organ preservation, without negatively influencing treatment toxicity or compliance.
This study compared the advantages and disadvantages of total neoadjuvant therapy (TNT) strategies for patients with locally advanced rectal cancer, compared with the more traditional multimodal neoadjuvant management strategies of long-course chemoradiotherapy (LCRT) or short-course radiotherapy (SCRT). A systematic review and network meta-analysis of exclusively RCTs was undertaken, comparing survival, recurrence, pathological, radiological, and oncological outcomes. The last date of the search was 14 December 2022. In total, 15 RCTs involving 4602 patients with locally advanced rectal cancer, conducted between 2004 and 2022, were included. TNT improved overall survival compared with LCRT (HR 0.73, 95 per cent credible interval 0.60 to 0.92) and SCRT (HR 0.67, 0.47 to 0.95). TNT also improved rates of distant metastasis compared with LCRT (HR 0.81, 0.69 to 0.97). Reduced overall recurrence was observed for TNT compared with LCRT (HR 0.87, 0.76 to 0.99). TNT showed an improved pCR compared with both LCRT (risk ratio (RR) 1.60, 1.36 to 1.90) and SCRT (RR 11.32, 5.00 to 30.73). TNT also showed an improvement in cCR compared with LCRT (RR 1.68, 1.08 to 2.64). There was no difference between treatments in disease-free survival, local recurrence, R0 resection, treatment toxicity or treatment compliance. This study provides further evidence that TNT has improved survival and recurrence benefits compared with current standards of care, and may increase the number of patients suitable for organ preservation, without negatively influencing treatment toxicity or compliance.
Abstract Background This study compared the advantages and disadvantages of total neoadjuvant therapy (TNT) strategies for patients with locally advanced rectal cancer, compared with the more traditional multimodal neoadjuvant management strategies of long-course chemoradiotherapy (LCRT) or short-course radiotherapy (SCRT). Methods A systematic review and network meta-analysis of exclusively RCTs was undertaken, comparing survival, recurrence, pathological, radiological, and oncological outcomes. The last date of the search was 14 December 2022. Results In total, 15 RCTs involving 4602 patients with locally advanced rectal cancer, conducted between 2004 and 2022, were included. TNT improved overall survival compared with LCRT (HR 0.73, 95 per cent credible interval 0.60 to 0.92) and SCRT (HR 0.67, 0.47 to 0.95). TNT also improved rates of distant metastasis compared with LCRT (HR 0.81, 0.69 to 0.97). Reduced overall recurrence was observed for TNT compared with LCRT (HR 0.87, 0.76 to 0.99). TNT showed an improved pCR compared with both LCRT (risk ratio (RR) 1.60, 1.36 to 1.90) and SCRT (RR 11.32, 5.00 to 30.73). TNT also showed an improvement in cCR compared with LCRT (RR 1.68, 1.08 to 2.64). There was no difference between treatments in disease-free survival, local recurrence, R0 resection, treatment toxicity or treatment compliance. Conclusion This study provides further evidence that TNT has improved survival and recurrence benefits compared with current standards of care, and may increase the number of patients suitable for organ preservation, without negatively influencing treatment toxicity or compliance. This study has demonstrated that total neoadjuvant therapy (TNT) has improved survival and recurrence benefits compared with current standards of care. TNT treatment strategies also improve radiological and oncological responses to treatment, and may increase the number of patients suitable for organ preservation, without negatively influencing treatment toxicity or compliance.
Author Creavin, Ben
Ryan, Éanna J
Martin, Seán T
Ryan, Odhrán K
Hanly, Ann
O’Reilly, Mary
Kennelly, Rory
Donnelly, Mark
Winter, Des C
McDermott, Ray
Author_xml – sequence: 1
  givenname: Mark
  orcidid: 0000-0002-9824-3312
  surname: Donnelly
  fullname: Donnelly, Mark
  email: mark.donnelly@ucdconnect.ie
– sequence: 2
  givenname: Odhrán K
  orcidid: 0000-0003-2750-4607
  surname: Ryan
  fullname: Ryan, Odhrán K
– sequence: 3
  givenname: Éanna J
  orcidid: 0000-0003-2609-0836
  surname: Ryan
  fullname: Ryan, Éanna J
– sequence: 4
  givenname: Ben
  orcidid: 0000-0001-8209-4810
  surname: Creavin
  fullname: Creavin, Ben
– sequence: 5
  givenname: Mary
  surname: O’Reilly
  fullname: O’Reilly, Mary
– sequence: 6
  givenname: Ray
  surname: McDermott
  fullname: McDermott, Ray
– sequence: 7
  givenname: Rory
  surname: Kennelly
  fullname: Kennelly, Rory
– sequence: 8
  givenname: Ann
  surname: Hanly
  fullname: Hanly, Ann
– sequence: 9
  givenname: Seán T
  surname: Martin
  fullname: Martin, Seán T
– sequence: 10
  givenname: Des C
  surname: Winter
  fullname: Winter, Des C
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37330950$$D View this record in MEDLINE/PubMed
BookMark eNpVUctO3TAQtSpQuTxW3SOvKjYBPxI76a5CFJCQuoF1NLEnNLdOfGs7oMt38YF1ygWpq5nRnId0ziHZm_yEhHzh7JyzRl5063jxMoHlWn8iKy5VVQiu6j2yYozpgkshD8hhjGvGuGSV-EwOpJaSNRVbkdd7n8DRCT3Y9fwEU6LpFwbYbOkThjhHGhNMFoL9HxMQ0oh5iylAwscBI-19WMh0hAke8d_X99R5A85tKdjMNGhpQLNYmuUK37JsevbhNx0xQZGZbhuHuBBD9vXj8JIpxg3TkGWy7wAuHpP9Pg882c0j8vDj6v7yprj7eX17-f2uMKIuUwG9qpitlZasZH2FUAqGHUjbyLoTgpfGGKhRYyNqpjQy3feNaXJ2ZWM7gfKInL3pboL_M2NM7ThEg85BzmKOraiFVqoUSmXo6Q46dyPadhOGEcK2fU86A76-Afy8-fhy1i4VtrnCdleh_AvrNJTR
CitedBy_id crossref_primary_10_2478_fco_2023_0014
crossref_primary_10_1016_j_ctro_2023_100721
crossref_primary_10_3390_cancers15174375
crossref_primary_10_4103_ijc_ijc_66_24
crossref_primary_10_1097_SLA_0000000000006161
crossref_primary_10_1007_s00384_023_04558_8
crossref_primary_10_1111_his_15192
crossref_primary_10_1016_j_clcc_2024_06_001
crossref_primary_10_1007_s00432_023_05139_6
crossref_primary_10_3390_cancers15153945
ContentType Journal Article
Copyright The Author(s) 2023. Published by Oxford University Press on behalf of BJS Society Ltd. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2023
The Author(s) 2023. Published by Oxford University Press on behalf of BJS Society Ltd. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Copyright_xml – notice: The Author(s) 2023. Published by Oxford University Press on behalf of BJS Society Ltd. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2023
– notice: The Author(s) 2023. Published by Oxford University Press on behalf of BJS Society Ltd. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
DBID NPM
7X8
DOI 10.1093/bjs/znad177
DatabaseName PubMed
MEDLINE - Academic
DatabaseTitle PubMed
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
PubMed

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
EISSN 1365-2168
EndPage 1330
ExternalDocumentID 37330950
10.1093/bjs/znad177
Genre Journal Article
GroupedDBID ---
.3N
.55
.GA
.GJ
.Y3
05W
0R~
10A
1L6
1OB
1OC
1ZS
23N
31~
33P
36B
3O-
3SF
3WU
4.4
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5RE
5VS
5WD
66C
6J9
6P2
702
7PT
8-0
8-1
8-3
8-4
8-5
8F7
8UM
930
A01
A03
AABZA
AACZT
AAESR
AAEVG
AAHHS
AAONW
AAPGJ
AAPXW
AAQQT
AARHZ
AASNB
AAUAY
AAVAP
AAWDT
AAYEP
AAZKR
ABCQN
ABCUV
ABEML
ABIJN
ABJNI
ABLJU
ABNHQ
ABOCM
ABPQP
ABPTD
ABPVW
ABQNK
ABWST
ABXVV
ACBWZ
ACCFJ
ACFBH
ACFRR
ACGFO
ACGFS
ACMXC
ACPOU
ACSCC
ACUTJ
ACXQS
ACYHN
ACZBC
ADBBV
ADEOM
ADIPN
ADIYS
ADIZJ
ADKYN
ADMGS
ADQBN
ADVEK
ADXAS
ADZMN
ADZOD
AEEZP
AEGXH
AEIMD
AENEX
AEQDE
AEUQT
AFBPY
AFFNX
AFFZL
AFGKR
AFPWT
AFXAL
AFYAG
AFYLJ
AFZJQ
AGMDO
AGQXC
AGUTN
AHMBA
AI.
AIAGR
AIURR
AIWBW
AJAOE
AJBDE
AJEEA
ALAGY
ALMA_UNASSIGNED_HOLDINGS
AMBMR
AMYDB
APJGH
AQDSO
ASPBG
ATGXG
ATUGU
AVNTJ
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BCRHZ
BDRZF
BEYMZ
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBS
EJD
EMOBN
ESX
EX3
F00
F01
F04
F5P
FEDTE
FLUFQ
FOEOM
FUBAC
G-S
G.N
GNP
GODZA
H.X
H13
HBH
HF~
HHY
HHZ
HVGLF
HZ~
IH2
IHE
IX1
J0M
J5H
JPC
KBUDW
KOP
KQQ
KSI
KSN
L7B
LATKE
LAW
LC2
LC3
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
M65
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N4W
N9A
NF~
NNB
NOMLY
O66
O9-
OAUYM
OCZFY
OHH
OIG
OJZSN
OPAEJ
OVD
OWPYF
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
QRW
R.K
RGB
RIG
RIWAO
RJQFR
ROL
ROX
RWI
RX1
RYL
SUPJJ
TEORI
TMA
UB1
V2E
V8K
V9Y
VH1
VVN
W8V
W99
WBKPD
WH7
WHWMO
WIB
WIH
WIJ
WIK
WJL
WOHZO
WQJ
WRC
WUP
WVDHM
WXI
X7M
XG1
XV2
YFH
YOC
YUY
ZGI
ZXP
ZY1
ZZTAW
~IA
~WT
NPM
7X8
ID FETCH-LOGICAL-c284t-af650d8673040f5ea420eba3d938b2214ccca8e7e928067e07ff9c916849db2e3
ISSN 0007-1323
IngestDate Fri Oct 25 23:57:23 EDT 2024
Wed Oct 16 00:38:17 EDT 2024
Wed Aug 28 03:15:16 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 10
Language English
License This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/pages/standard-publication-reuse-rights)
The Author(s) 2023. Published by Oxford University Press on behalf of BJS Society Ltd. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c284t-af650d8673040f5ea420eba3d938b2214ccca8e7e928067e07ff9c916849db2e3
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
ORCID 0000-0002-9824-3312
0000-0001-8209-4810
0000-0003-2750-4607
0000-0003-2609-0836
PMID 37330950
PQID 2827664266
PQPubID 23479
PageCount 15
ParticipantIDs proquest_miscellaneous_2827664266
pubmed_primary_37330950
oup_primary_10_1093_bjs_znad177
PublicationCentury 2000
PublicationDate 2023-09-06
PublicationDateYYYYMMDD 2023-09-06
PublicationDate_xml – month: 09
  year: 2023
  text: 2023-09-06
  day: 06
PublicationDecade 2020
PublicationPlace US
PublicationPlace_xml – name: US
– name: England
PublicationTitle British journal of surgery
PublicationTitleAlternate Br J Surg
PublicationYear 2023
Publisher Oxford University Press
Publisher_xml – name: Oxford University Press
SSID ssj0013052
Score 2.5283618
Snippet Abstract Background This study compared the advantages and disadvantages of total neoadjuvant therapy (TNT) strategies for patients with locally advanced...
This study compared the advantages and disadvantages of total neoadjuvant therapy (TNT) strategies for patients with locally advanced rectal cancer, compared...
BACKGROUNDThis study compared the advantages and disadvantages of total neoadjuvant therapy (TNT) strategies for patients with locally advanced rectal cancer,...
SourceID proquest
pubmed
oup
SourceType Aggregation Database
Index Database
Publisher
StartPage 1316
Title Total neoadjuvant therapy versus standard neoadjuvant treatment strategies for the management of locally advanced rectal cancer: network meta-analysis of randomized clinical trials
URI https://www.ncbi.nlm.nih.gov/pubmed/37330950
https://search.proquest.com/docview/2827664266
Volume 110
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaWcuGCingthWIkbig0cRIn6a0qXVWotFK1K-0tcmJbUNEEkQRp93dx4td1JnZepYfCJdpN4pHW8-14xv5mhpD3TAkWyEw7ATi3TsA85WTgJzu5m0iuEyGZxmzkL-f8dBV8Xofr2ezPiLXU1NnHfHtnXsn_aBXugV4xS_YfNNsLhRvwGfQLV9AwXO-n4xJTGQtVCnnVgEvc5iVikYAPSLZoqmGjYPJOzy2v6q5QRM82vO7pMOhGtivd983AFED7iBVF8FvbYLIwNHLsRC0cMapwAmugLK-_bWFQn33ZtgipJufItqbSqIBFNUrURg_bMHE2txOLLjdm6_ZCfjWn_V4xbNl2D_FBnIiiEMPx1zH8_F-2S73Ng7O7HsxvaV22Zrax1C09zzM9eXpTbimyFrPuyDJ7vsdHqzyE5u6dK4iprpVdwb9osS2E9GyXmUml7vOLdLE6O0uXJ-vlA_KQgZFDOuGnSzacYLkhs_mgIPIABB5YcbdSKf-KaFrPZrlLHtuQhB4ZfD0hM1U8Jb9bbNERbqjFFjXYoh22pu902KIDtihgCwfTAVu01NRii3bYogZb1GDrkFpk0QmycOCALNohixpkPSOrxcny-NSxHT6cHNyi2hEaAgQZc1hmAleHSgTMVZnwJcxnxpgX5GBgYhWpBAkAkXIjrZMcIpo4SGTGlP-c7BRloV4SmgCaVJh5XMYs0DxP3Eho7AXBucpB4py8hVlPf5gaLqnhXvgp6CW1epmTd51GUrCxeHAmYAabKmUxizhHX3ZOXhhV9YL8CJCUhO6re4zeI48GLL8mO_XPRr0Bn7bO9lvw3AAmubJp
link.rule.ids 315,783,787,27938,27939
linkProvider Wiley-Blackwell
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Total+neoadjuvant+therapy+versus+standard+neoadjuvant+treatment+strategies+for+the+management+of+locally+advanced+rectal+cancer%3A+network+meta-analysis+of+randomized+clinical+trials&rft.jtitle=British+journal+of+surgery&rft.au=Donnelly%2C+Mark&rft.au=Ryan%2C+Odhr%C3%A1n+K&rft.au=Ryan%2C+%C3%89anna+J&rft.au=Creavin%2C+Ben&rft.date=2023-09-06&rft.eissn=1365-2168&rft.volume=110&rft.issue=10&rft.spage=1316&rft.epage=1330&rft_id=info:doi/10.1093%2Fbjs%2Fznad177&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0007-1323&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0007-1323&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0007-1323&client=summon